Worth reading
61In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
495
¥ million (increase from the initial full-year net sales forecast)Wording
Conditional
How definitive the wording is.Contents of this document
Supplementary materials to the earnings reportFiscal year ending February 2027, second quarter11 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥4,935 million+18.9%
Operating profit¥641 million+438.6%
Operating profit margin13 %
Results for the three months of the current quarter
Net Sales
¥2,743 million
Operating profit
¥442 million
Operating profit margin
16.1 %
EBITDA
¥604 million
EBITDA margin
22 %
Full-year earnings forecast
Net Sales
¥10,323 million
Operating profit
¥1,367 million
Operating profit margin
13.2 %
EBITDA
¥2,076 million
EBITDA margin
20.1 %
Semiconductor revenue
¥7,241 million
Healthcare revenue
¥1,219 million
New Business Revenue
¥1,864 million
What the company explained in this material
Self-assessment against the planThe company's self-assessment against its own plan.
Both revenue and operating profit exceeded forecasts.Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
- Revision to full-year semiconductor revenue forecast¥838 million
- Revision to full-year healthcare revenue forecast¥-632 million
- Revision to full-year new business area revenue forecast¥288 million
- Revision to full-year company-wide revenue forecast¥495 million
- Revision to full-year company-wide operating profit forecast¥434 million
Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
- The second-half forecast was reviewed based on projects with a high likelihood of orders at present.
New initiatives
- Commercialization of deep-ultraviolet femtosecond lasers combining Fluence's femtosecond laser technology with the Company's wavelength-conversion technology
- Invited Kayama Susumu (香山晋) to serve as an advisor on management strategy
- ¥1,455 million investment to expand production capacity for Faraday rotators for data centers
Key KPIsA metric the company considers important as a management benchmark.
- EBITDA¥969 millionYear on year against the same period last year+705.0%
- EBITDA margin19.6 %Year on year against the same period last year+13.3%
- First-half semiconductor order intake¥3,456 million
- Semiconductor order backlog at the end of the second quarter¥3,390 million
- Net Debt/EBITDA2.6 times
- Equity ratio34.7 %
Segment results
Semiconductors
Net Sales
¥3,259 million
Year on year against the same period last year+70.0%
Healthcare
Net Sales
¥874 million
New domain
Net Sales
¥800 million
Medium-term management plan targets
Fiscal year ending February 2028
Operating profit margin12 %
EBITDA margin22 %
Fiscal year ending February 2029
Net Sales13,000 %
Operating profit margin14 %
EBITDA margin23 %
Financial targets
Net Debt/EBITDA
2.6 times
Actual resultsEnd of the second quarter of the fiscal year ending February 2027
Debt-to-equity ratio
1.3 times
Actual resultsEnd of the second quarter of the fiscal year ending February 2027
Equity ratio
34.7 %
Actual resultsEnd of the second quarter of the fiscal year ending February 2027
Market Size / Share
Wafer Fab Equipment (WFE) Market
23.2 2026 year-on-year growth rate %
Orders received and order backlog
Orders received
¥3,456 million
Order backlog
¥3,390 million
Capital expenditures
3,000 Just under ¥1 million revised forecast for the fiscal year ending February 2027
| Item | Details |
|---|---|
| Document type | Supplementary materials to the earnings report |
| Fiscal Period Covered | Fiscal year ending February 2027, second quarter |
| Net Sales | ¥4,935 million (YoY +18.9%) |
| Operating profit | ¥641 million (YoY +438.6%) |
| Operating profit margin | 13 % |
| Results for the three months of the current quarter | Net Sales ¥2,743 million / Operating profit ¥442 million / Operating profit margin 16.1 % / EBITDA ¥604 million / EBITDA margin 22 % |
| Full-year earnings forecast | Net Sales ¥10,323 million / Operating profit ¥1,367 million / Operating profit margin 13.2 % / EBITDA ¥2,076 million / EBITDA margin 20.1 % / Semiconductor revenue ¥7,241 million / Healthcare revenue ¥1,219 million / New Business Revenue ¥1,864 million |
| Self-assessment against the plan | Both revenue and operating profit exceeded forecasts. |
| Segment results | Semiconductors Net Sales ¥3,259 million / Year on year against the same period last year 70 % increase / Healthcare Net Sales ¥874 million / Year on year against the same period last year Not disclosed / New domain Net Sales ¥800 million / Year on year against the same period last year Not disclosed |
| Breakdown of Factors Affecting the Change | Factors Revision to full-year semiconductor revenue forecast / Amount ¥838 million, Factors Revision to full-year healthcare revenue forecast / Amount ¥-632 million, Factors Revision to full-year new business area revenue forecast / Amount ¥288 million, Factors Revision to full-year company-wide revenue forecast / Amount ¥495 million, Factors Revision to full-year company-wide operating profit forecast / Amount ¥434 million |
| Key KPIs | Indicator name EBITDA / Value ¥969 million / Year on year against the same period last year ¥705 million, Indicator name EBITDA margin / Value 19.6 % / Year on year against the same period last year 13.3 %, Indicator name First-half semiconductor order intake / Value ¥3,456 million / Year on year against the same period last year Not disclosed, Indicator name Semiconductor order backlog at the end of the second quarter / Value ¥3,390 million / Year on year against the same period last year Not disclosed, Indicator name Net Debt/EBITDA / Value 2.6 times / Year on year against the same period last year Not disclosed, Indicator name Equity ratio / Value 34.7 % / Year on year against the same period last year Not disclosed |
| Assumptions Underlying the Business Outlook | The second-half forecast was reviewed based on projects with a high likelihood of orders at present. |
| Medium-term management plan targets | Fiscal year ending February 2028 Operating profit margin 12 % / EBITDA margin 22 % / Fiscal year ending February 2029 Net Sales 13,000 % / Operating profit margin 14 % / EBITDA margin 23 % |
| Financial targets | Net Debt/EBITDA 2.6 times / Debt-to-equity ratio 1.3 times / Equity ratio 34.7 % |
| Capital expenditures | 3,000 Just under ¥1 million (revised forecast for the fiscal year ending February 2027) |
| Orders received and order backlog | Orders received ¥3,456 million / Order backlog ¥3,390 million |
| Market Size / Share | Wafer Fab Equipment (WFE) Market 23.2 2026 year-on-year growth rate (%) |
| New initiatives | Commercialization of deep-ultraviolet femtosecond lasers combining Fluence's femtosecond laser technology with the Company's wavelength-conversion technology, Invited Kayama Susumu (香山晋) to serve as an advisor on management strategy, ¥1,455 million investment to expand production capacity for Faraday rotators for data centers |
Items this document does not state (13)
Ordinary incomeNet incomeGross Profit MarginSelling, general and administrative expensesProgress against full-year forecastUnit price and quantity metricsNumber of stores and locationsNumber of employeesRisk amount incorporated into the outlookAnnual DividendPayout ratioAcquisition of treasury sharesKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.In the semiconductor business, shipments of single-crystal and laser products increased, while in the new business areas, shipments of Faraday rotators for data centers increased. Accordingly, revenue forecasts for both businesses were revised upward. For the healthcare business, the second-half forecast was reviewed based on projects with a high likelihood of orders, in light of worsening procurement conditions and rising prices for key raw materials.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.